Journal article
A review of cost–effectiveness of palivizumab for respiratory syncytial virus
Abstract
Palivizumab prophylaxis has been demonstrated to reduce the number of hospitalizations attributable to respiratory syncytial virus in high-risk infants. However, as palivizumab acquisition costs are high, quantifying cost-effectiveness is important. The primary aim of this review was to examine the cost-effectiveness of palivizumab across numerous indications in high-risk infants and to report on factors that may impact outcomes. A systematic …
Authors
Hussman JM; Li A; Paes B; Lanctôt KL
Journal
Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 12, No. 5, pp. 553–567
Publisher
Taylor & Francis
Publication Date
10 2012
DOI
10.1586/erp.12.45
ISSN
1473-7167